利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.041 秒)

    Heterocyclic H3 Antagonists
    1.
    发明申请
    Heterocyclic H3 Antagonists 失效
    杂环H3拮抗剂

    公开(公告)号：US20100267721A1

    公开(公告)日：2010-10-21

    申请号：US12663103

    申请日：2008-05-19

    申请人： Rolf Hohlweg ,  Jane Marie Lundbeck ,  Johannes Cornelis de Jong

    发明人： Rolf Hohlweg ,  Jane Marie Lundbeck ,  Johannes Cornelis de Jong

    IPC分类号： A61K31/5377 ,  C07D401/14 ,  A61K31/4545 ,  C07D413/14 ,  A61K31/497 ,  C07D403/04 ,  A61K31/501 ,  A61P3/04 ,  A61P1/16 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P11/06 ,  A61P19/02 ,  A61P25/28 ,  A61P1/12 ,  A61P35/00

    CPC分类号： C07D405/14 ,  C07D401/04 ,  C07D401/14 ,  C07D413/10 ,  C07D413/14

    摘要： Compound of formula (I) wherein W, X, Y, Z is —C(R′)═ or N; R1 is hydrogen or alkyl, V is N or C (i.e. carbon), A is a bond or an alkylene linker with 1 to 3 carbon atoms, with the proviso that when A is a bond, V must be CH, R is ethyl, propyl, a branched C3-6 alkyl or a cyclic C3-8 alkyl, m and n is 1-3, D is heteroaryl optionally substituted with halogen, hydroxy, cyano, alkyl, cycloalkyl, alkoxy, —(CH2)o—(C═O)p—NR2R3, or D is aryl optionally substituted with one or more of the groups independently selected from hydrogen, halogen, hydroxy, cyano, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, alkylsulfinyl, heterocyclyl, heterocyclylalkyl, heterocyclyl-alkoxy, heterocyclylcarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarboxy, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, arylcarbonylamino, aryl-carbonylaminoalkyl, heteroarylcarbonylamino or heteroarylcarbonylaminoalkyl, —(CH2)0—(C═O)p—NR2R3, wherein o is 0-3, p is 0 or 1, and R2 and R3 independently are hydrogen, alkyl or cycloalkyl; or R2 and R3, can together with the attached nitrogen form a heterocyclyl group, and salts and solvates thereof have binding affinity for the histamine H3 receptor.

    摘要翻译： 式（I）化合物，其中W，X，Y，Z为-C（R'）=或N; R1是氢或烷基，V是N或C（即碳），A是具有1至3个碳原子的键或亚烷基接头，条件是当A是键时，V必须是CH，R是乙基， 丙基，支链C 3-6烷基或环C 3-8烷基，m和n为1-3，D为任选被卤素，羟基，氰基，烷基，环烷基，烷氧基， - （CH 2）o - （C ≡O）p-NR2R3，或D是任选被一个或多个独立地选自氢，卤素，羟基，氰基，烷基，环烷基，卤代烷基，烷氧基，卤代烷氧基，烷基磺酰基，烷基亚磺酰基，杂环基，杂环基烷基，杂环基 - 烷基羰基，烷氧基羰基，烷氧基烷基，烷基羰基氨基，烷基羰基氨基烷基，芳基羰基氨基，芳基 - 羰基氨基烷基，杂芳基羰基氨基或杂芳基羰基氨基烷基， - （CH2）O-（C = O）p-NR2R3，其中o为0 -3，p为0或1，R2和R3独立地为氢，烷基o 环烷基 或R 2和R 3可以与连接的氮一起形成杂环基，其盐和溶剂合物对组胺H3受体具有结合亲和力。

    Heterocyclic H3 antagonists
    2.
    发明授权
    Heterocyclic H3 antagonists 失效
    杂环H3拮抗剂

    公开(公告)号：US08344001B2

    公开(公告)日：2013-01-01

    申请号：US12663103

    申请日：2008-05-19

    申请人： Rolf Hohlweg ,  Jane Marie Lundbeck ,  Johannes Cornelis de Jong

    发明人： Rolf Hohlweg ,  Jane Marie Lundbeck ,  Johannes Cornelis de Jong

    IPC分类号： A61K31/44

    CPC分类号： C07D405/14 ,  C07D401/04 ,  C07D401/14 ,  C07D413/10 ,  C07D413/14

    摘要： Compound of formula (I) wherein W, X, Y, Z is —C(R1)═ or N; R1 is hydrogen or alkyl, V is N or C (i.e. carbon), A is a bond or an alkylene linker with 1 to 3 carbon atoms, with the proviso that when A is a bond, V must be CH, R is ethyl, propyl, a branched C3-6 alkyl or a cyclic C3-8 alkyl, m and n is 1-3, D is heteroaryl optionally substituted with halogen, hydroxy, cyano, alkyl, cycloalkyl, alkoxy, —(CH2)0—(C═O)p—NR2R3, or D is aryl optionally substituted with one or more of the groups independently selected from hydrogen, halogen, hydroxy, cyano, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, alkylsulfinyl, heterocyclyl, heterocyclylalkyl, heterocyclyl-alkoxy, heterocyclylcarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarboxy, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, arylcarbonylamino, aryl-carbonylaminoalkyl, heteroarylcarbonylamino or heteroarylcarbonylaminoalkyl, —(CH2)0—(C═O)p—NR2R3, wherein o is 0-3, p is 0 or 1, and R2 and R3 independently are hydrogen, alkyl or cycloalkyl; or R2 and R3, can together with the attached nitrogen form a heterocyclyl group, and salts and solvates thereof have binding affinity for the histamine H3 receptor.

    摘要翻译： 式（I）的化合物，其中W，X，Y，Z是-C（R 1）=或N; R1是氢或烷基，V是N或C（即碳），A是具有1至3个碳原子的键或亚烷基接头，条件是当A是键时，V必须是CH，R是乙基， 丙基，支链C 3-6烷基或环C 3-8烷基，m和n是1-3，D是任选被卤素，羟基，氰基，烷基，环烷基，烷氧基， - （CH 2）O-（C ≡O）p-NR2R3，或D是任选被一个或多个独立地选自氢，卤素，羟基，氰基，烷基，环烷基，卤代烷基，烷氧基，卤代烷氧基，烷基磺酰基，烷基亚磺酰基，杂环基，杂环基烷基，杂环基 - 烷基羰基，烷氧基羰基，烷氧基烷基，烷基羰基氨基，烷基羰基氨基烷基，芳基羰基氨基，芳基 - 羰基氨基烷基，杂芳基羰基氨基或杂芳基羰基氨基烷基， - （CH2）O-（C = O）p-NR2R3，其中o为0 -3，p为0或1，R2和R3独立地为氢，烷基o 环烷基 或R 2和R 3可以与连接的氮一起形成杂环基，其盐和溶剂合物对组胺H3受体具有结合亲和力。

    Novel Medicaments
    6.
    发明申请
    Novel Medicaments 失效
    新药

    公开(公告)号：US20090312309A1

    公开(公告)日：2009-12-17

    申请号：US11917823

    申请日：2006-06-30

    申请人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    发明人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    IPC分类号： A61K31/5513 ,  A61K31/5377 ,  A61K31/501 ,  A61K31/497 ,  C07D413/14 ,  C07D403/04

    CPC分类号： C07D213/74 ,  C07D213/84 ,  C07D213/87 ,  C07D237/20 ,  C07D403/04 ,  C07D403/12 ,  C07D417/10

    摘要： Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.

    摘要翻译： 定义与组胺H3受体相互作用的新型化合物。 这些化合物特别可用于治疗组胺H3相互作用有益的各种疾病或病症。 因此，该化合物可用于例如治疗中枢神经系统，周围神经系统，心血管系统，肺系统，胃肠系统和内分泌系统的疾病。 该新化合物具有由在环中含有至少一个氮原子和两个碳原子的6元芳香环组成的核心，并且在该环的其余位置上有碳原子或氮原子。

    Medicaments
    7.
    发明授权
    Medicaments 有权
    药剂

    公开(公告)号：US08846677B2

    公开(公告)日：2014-09-30

    申请号：US13472090

    申请日：2012-05-15

    申请人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    发明人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    IPC分类号： A61K31/501 ,  C07D401/00 ,  C07D409/00

    CPC分类号： C07D213/74 ,  C07D213/84 ,  C07D213/87 ,  C07D237/20 ,  C07D403/04 ,  C07D403/12 ,  C07D417/10

    摘要： Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.

    摘要翻译： 定义与组胺H3受体相互作用的新型化合物。 这些化合物特别可用于治疗组胺H3相互作用有益的各种疾病或病症。 因此，该化合物可用于例如治疗中枢神经系统，周围神经系统，心血管系统，肺系统，胃肠系统和内分泌系统的疾病。 该新化合物具有由在环中含有至少一个氮原子和两个碳原子的6元芳香环组成的核心，并且在该环的其余位置上有碳原子或氮原子。

    Medicaments
    8.
    发明授权
    Medicaments 失效
    药剂

    公开(公告)号：US08501739B2

    公开(公告)日：2013-08-06

    申请号：US11917823

    申请日：2006-06-30

    申请人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    发明人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    IPC分类号： A61K31/50 ,  C07D401/00

    CPC分类号： C07D213/74 ,  C07D213/84 ,  C07D213/87 ,  C07D237/20 ,  C07D403/04 ,  C07D403/12 ,  C07D417/10

    摘要： Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.

    摘要翻译： 定义与组胺H3受体相互作用的新型化合物。 这些化合物特别可用于治疗组胺H3相互作用有益的各种疾病或病症。 因此，该化合物可用于例如治疗中枢神经系统，周围神经系统，心血管系统，肺系统，胃肠系统和内分泌系统的疾病。 该新化合物具有由在环中含有至少一个氮原子和两个碳原子的6元芳香环组成的核心，并且在该环的其余位置上有碳原子或氮原子。

    Novel Medicaments
    10.
    发明申请
    Novel Medicaments 有权
    新药

    公开(公告)号：US20120232078A1

    公开(公告)日：2012-09-13

    申请号：US13472090

    申请日：2012-05-15

    申请人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    发明人： Rolf Hohlweg ,  Knud Erik Andersen ,  Jan Lindy Sorensen ,  Jane Marie Lundbeck

    IPC分类号： A61K31/506 ,  A61P3/04 ,  A61P25/24 ,  A61K31/5377

    CPC分类号： C07D213/74 ,  C07D213/84 ,  C07D213/87 ,  C07D237/20 ,  C07D403/04 ,  C07D403/12 ,  C07D417/10

    摘要： Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.

    摘要翻译： 定义与组胺H3受体相互作用的新型化合物。 这些化合物特别可用于治疗组胺H3相互作用有益的各种疾病或病症。 因此，该化合物可用于例如治疗中枢神经系统，周围神经系统，心血管系统，肺系统，胃肠系统和内分泌系统的疾病。 该新化合物具有由在环中含有至少一个氮原子和两个碳原子的6元芳香环组成的核心，并且在该环的其余位置上有碳原子或氮原子。